Possible factors contributing to the failure of RSG in human clinical trials include species differences in AD-like disease progression and the action of RSG and its PPARγ mechanism, the low BBB permeability of RSG, as well as the recruitment of suboptimal or wrong target groups in clinical trials [24,80]. Here, PPARG is linked to Alzheimer disease.